the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to
affect more than 5% of the population and is associated with chronically elevated serum
androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative
impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive
disease during pregnancy,and preterm birth,which is partially related with the
hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic
drug.At present, there is no direct evidence that Diane-35 has a positive effect on the
clinical outcome of polycystic ovary syndrome patients undergoing In-vitro
fertilization/Intracytoplasmic sperm injection.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Treatments:
Cyproterone Cyproterone Acetate Cyproterone acetate, ethinyl estradiol drug combination